Ocuphire Announces APX3330 and Nyxol Data Presentations at ASCRS 2023 and Eyecelerator

FARMINGTON HILLS, Mich., May 02, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations featuring results from the Company’s recently completed trials of APX3330 and Nyxol at…Read More